Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs